Sunshine Biopharma Inc
SBFM1.310USD
0.000
Close 12/24, 13:00（ET）Quotes delayed by 15 min
5.97MMarket Cap
0.25P/E TTM
More Details of Sunshine Biopharma Inc Company
Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.
Sunshine Biopharma Inc Info
Ticker SymbolSBFM
Company nameSunshine Biopharma Inc
IPO dateAug 15, 2008
CEOSlilaty (Steve N)
Number of employees52
Security typeOrdinary Share
Fiscal year-endAug 15
Address333 Las Olas Way
CityFORT LAUDERDALE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33301
Phone19543300684
Websitehttps://www.sunshinebiopharma.com/
Ticker SymbolSBFM
IPO dateAug 15, 2008
CEOSlilaty (Steve N)
Company Executives of Sunshine Biopharma Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Steve N. Slilaty
Dr. Steve N. Slilaty
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
61.00
--
Mr. Camille Sebaaly
Mr. Camille Sebaaly
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
60.00
--
Dr. Abderrazzak Merzouki
Dr. Abderrazzak Merzouki
Chief Operating Officer, Director
Chief Operating Officer, Director
59.00
--
Mr. Michel Roy
Mr. Michel Roy
Chief Commercial Officer
Chief Commercial Officer
1.00
--
Dr. Rabi Kiderchah, M.D.
Dr. Rabi Kiderchah, M.D.
Independent Director
Independent Director
--
--
Dr. Andrew M. Keller
Dr. Andrew M. Keller
Independent Director
Independent Director
--
--
Mr. David Natan
Mr. David Natan
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Steve N. Slilaty
Dr. Steve N. Slilaty
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
61.00
--
Mr. Camille Sebaaly
Mr. Camille Sebaaly
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
60.00
--
Dr. Abderrazzak Merzouki
Dr. Abderrazzak Merzouki
Chief Operating Officer, Director
Chief Operating Officer, Director
59.00
--
Mr. Michel Roy
Mr. Michel Roy
Chief Commercial Officer
Chief Commercial Officer
1.00
--
Dr. Rabi Kiderchah, M.D.
Dr. Rabi Kiderchah, M.D.
Independent Director
Independent Director
--
--
Dr. Andrew M. Keller
Dr. Andrew M. Keller
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Nov 20
Updated: Thu, Nov 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
L1 Global Manager Pty Limited
2.90%
Citadel Advisors LLC
1.59%
Renaissance Technologies LLC
1.14%
DRW Securities, LLC
0.92%
Two Sigma Investments, LP
0.79%
Other
92.67%
Shareholders
Shareholders
Proportion
L1 Global Manager Pty Limited
2.90%
Citadel Advisors LLC
1.59%
Renaissance Technologies LLC
1.14%
DRW Securities, LLC
0.92%
Two Sigma Investments, LP
0.79%
Other
92.67%
Shareholder Types
Shareholders
Proportion
Investment Advisor
3.90%
Hedge Fund
3.51%
Research Firm
0.10%
Individual Investor
0.04%
Other
92.44%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
33
128.14K
2.61%
-276.56K
2025Q2
40
174.71K
3.84%
-217.75K
2025Q1
40
223.71K
4.97%
+181.45K
2024Q4
39
166.72K
8.34%
+112.42K
2024Q3
38
41.53K
13.09%
+24.77K
2024Q2
37
17.39K
14.86%
+11.35K
2024Q1
40
9.43K
19.69%
+5.56K
2023Q4
38
3.43K
26.72%
+270.00
2023Q3
34
2.71K
21.06%
-1.08K
2023Q2
34
3.32K
29.59%
+626.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Citadel Advisors LLC
63.43K
1.39%
+63.43K
--
Jun 30, 2025
Renaissance Technologies LLC
54.09K
1.19%
+54.09K
--
Jun 30, 2025
SBI Securities Co., Ltd.
6.69K
0.15%
+1.47K
+28.16%
Jun 30, 2025
Morgan Stanley Smith Barney LLC
3.83K
0.08%
--
--
Jun 30, 2025
Chamoun (Malek)
1.85K
0.04%
--
--
Apr 01, 2025
UBS Financial Services, Inc.
206.00
0%
-19.68K
-98.96%
Jun 30, 2025
Osaic Holdings, Inc.
152.00
0%
+150.00
+7500.00%
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 06, 2024
Merger
20→1
Aug 06, 2024
Merger
20→1
Aug 06, 2024
Merger
20→1
Aug 06, 2024
Merger
20→1
Apr 12, 2024
Merger
100→1
Apr 12, 2024
Merger
100→1
Date
Type
Ratio
Aug 06, 2024
Merger
20→1
Aug 06, 2024
Merger
20→1
Aug 06, 2024
Merger
20→1
Aug 06, 2024
Merger
20→1
Apr 12, 2024
Merger
100→1
Apr 12, 2024
Merger
100→1
Apr 12, 2024
Merger
100→1
Apr 12, 2024
Merger
100→1
FAQs
Who are the top five shareholders of Sunshine Biopharma Inc?
The top five shareholders of Sunshine Biopharma Inc are:
Citadel Advisors LLC holds 63.43K shares, accounting for 1.39% of the total shares.
Renaissance Technologies LLC holds 54.09K shares, accounting for 1.19% of the total shares.
SBI Securities Co., Ltd. holds 6.69K shares, accounting for 0.15% of the total shares.
Morgan Stanley Smith Barney LLC holds 3.83K shares, accounting for 0.08% of the total shares.
Chamoun (Malek) holds 1.85K shares, accounting for 0.04% of the total shares.
Citadel Advisors LLC holds 63.43K shares, accounting for 1.39% of the total shares.
Renaissance Technologies LLC holds 54.09K shares, accounting for 1.19% of the total shares.
SBI Securities Co., Ltd. holds 6.69K shares, accounting for 0.15% of the total shares.
Morgan Stanley Smith Barney LLC holds 3.83K shares, accounting for 0.08% of the total shares.
Chamoun (Malek) holds 1.85K shares, accounting for 0.04% of the total shares.
What are the top three shareholder types of Sunshine Biopharma Inc?
The top three shareholder types of Sunshine Biopharma Inc are:
L1 Global Manager Pty Limited
Citadel Advisors LLC
Renaissance Technologies LLC
L1 Global Manager Pty Limited
Citadel Advisors LLC
Renaissance Technologies LLC
How many institutions hold shares of Sunshine Biopharma Inc (SBFM)?
As of 2025Q3, 33 institutions hold shares of Sunshine Biopharma Inc, with a combined market value of approximately 128.14K, accounting for 2.61% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -1.22%.
What is the biggest source of revenue for Sunshine Biopharma Inc?
In --, the -- business generated the highest revenue for Sunshine Biopharma Inc, amounting to -- and accounting for --% of total revenue.
